Table 1.
Patient baseline characteristics
| Placebo (n=116) | Lebrikizumab 37.5 mg (n=117) | Lebrikizumab 125 mg (n=112) | Lebrikizumab 250 mg (n=118) | |
|---|---|---|---|---|
| Age, mean (SD), years | 50.0 (13.3) | 48.7 (13.1) | 46.8 (13.4) | 47.9 (11.9) |
| Female, n (%) | 74 (63.8) | 72 (61.5) | 60 (53.6) | 69 (58.5) |
| Weight, mean (SD), kg | 86.1 (17.3) | 85.2 (17.4) | 86.7 (18.1) | 87.1 (17.0) |
| Race | ||||
| White | 84 (72.4) | 91 (77.8) | 87 (77.7) | 86 (72.9) |
| Black | 25 (21.6) | 21 (17.9) | 17 (15.2) | 17 (14.4) |
| Asian | 1 (0.9) | 4 (3.4) | 2 (1.8) | 6 (5.1) |
| Other | 6 (5.2) | 1 (0.9) | 6 (5.4) | 9 (7.6) |
| Ethnicity | ||||
| Hispanic or Latino | 14 (12.1) | 13 (11.1) | 6 (5.4) | 18 (15.3) |
| Not Hispano or Latino | 102 (87.9) | 104 (88.9) | 105 (93.8) | 100 (84.7) |
| Not reported | 0 | 0 | 1 (0.9) | 0 |
| Number of asthma exacerbations in the last 12 months, n (%) | ||||
| 0 | 59 (50.9) | 60 (51.3) | 61 (54.5) | 62 (52.5) |
| 1–2 | 47 (40.5) | 47 (40.2) | 43 (38.4) | 44 (37.3) |
| ≥3 | 10 (8.6) | 10 (8.5) | 8 (7.1) | 12 (10.2) |
| Baseline ICS* dose ≥1000 μg/day+LABA use, n (%) | 46 (39.7) | 49 (41.9) | 53 (47.3) | 54 (45.8) |
| Pre-bronchodilator FEV1 (% of predicted), mean (SD) | 62.7 (10.2) | 62.5 (10.2) | 62.8 (10.9) | 60.9 (10.2) |
| Best bronchodilator response (% relative improvement), mean (SD) | 21.9 (11.4) | 23.4 (16.7) | 23.2 (17.5) | 23.8 (14.6) |
| AQLQ(S), mean (SD) | 4.4 (0.8) | 4.5 (0.8) | 4.5 (0.7) | 4.4 (0.8) |
| ACQ-5, mean (SD) | 3.3 (0.8) | 3.2 (0.8) | 3.2 (0.7) | 3.3 (1.0) |
| IgE, median, IU/mL | 149.0 | 153.0 | 146.5 | 124.0 |
| Periostin, median (day −7) (ng/mL) | 46.4 | 49.5 | 47.3 | 48.7 |
| <50, n (%) | 74 (63.8) | 60 (51.3) | 69 (61.6) | 65 (55.1) |
| ≥50 , n (%) | 42 (36.2) | 57 (48.7) | 43 (38.4) | 53 (44.9) |
| Eosinophils, mean (SD),103/μL | 0.36 (0.69) | 0.30 (0.18) | 0.28 (0.22) | 0.31 (0.30) |
| FeNO, mean (SD), ppb | 26.8 (24.9) | 27.8 (30.0) | 31.3 (24.6) | 29.3 (27.6) |
*Fluticasone dry powder inhaler or equivalent.
ACQ-5, Asthma Control Questionnaire-5; AQLQ(S), Asthma Quality-of-Life Questionnaire (standardised); ICS, inhaled corticosteroid; IgE, immunoglobulin E; LABA, long-acting β2-agonist.